Nutlin-3a

For research use only. Not for use in humans.

目录号:S8059 别名: (-)-Nutlin-3

Nutlin-3a Chemical Structure

CAS No. 675576-98-4

Nutlin-3a 是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。Nutlin-3a 可诱导p53依赖的自噬和细胞凋亡。

规格 价格 库存 购买数量  
RMB 1624.68 现货
RMB 5480.74 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Nutlin-3a发表文献39篇:

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3a 是Nutlin-3的活性对映体,抑制p53/MDM2相互作用,无细胞试验中IC50为90 nM。Nutlin-3a 可诱导p53依赖的自噬和细胞凋亡。
特性 高度选择性的MDM2抑制剂与对MDMX低得多的效果。对含野生型p53的肿瘤最有效。
靶点
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
体外研究

Nutlin-3α从MDM2蛋白的结合口袋置换p53,由此将p53从抑制和蛋白酶体降解状态释放出来,从而导致诱导其下游靶点,细胞周期停滞和细胞凋亡。七天孵育10 μM nutlin-3a导致了NIH3T3细胞的生长抑制达90%以上。[1] Nutlin-3α稳定并激活p53基因,以剂量依赖性的方式诱导p21的表达。[1] Nutlin-3A有效地减少S期细胞至0.2-2%,并增加了G1-和G2/M期细胞。[1] 在40小时后,Nutlin-3a诱导约60% SJSA-1和MHM细胞的凋亡,而到60小时后,凋亡细胞分别达到85%和65%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXGVpZOUUN3ME2wMlYyOjN5IN88US=> NFXSRWZUSU6JRWK=
H4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{THNmlEPTB;MD62OlI5KM7:TR?= NIfHWI9USU6JRWK=
PA-1 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwOEewPVYh|ryP NUe1XpBRW0GQR1XS
NKM-1 M13VcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fqTWlEPTB;MT6wOFk{OSEQvF2= NGSzbHpUSU6JRWK=
NEC8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFwMkG1O|Ih|ryP NXXHVGV4W0GQR1XS
EoL-1-cell NHXSfmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHMNY5KSzVyPUGuNlY4ODFizszN M1zWTnNCVkeHUh?=
K5 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LU[mlEPTB;MT60NlA4OiEQvF2= NXP2W4JFW0GQR1XS
QIMR-WIL NYTFO5hDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLtdZRFUUN3ME2xMlYxQDV2IN88US=> NYXOfWFCW0GQR1XS
MOLT-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4npfWlEPTB;MT63PFYxPCEQvF2= MXzTRW5ITVJ?
CHP-212 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjMS5p7UUN3ME2xMlgyOzZ7IN88US=> MWDTRW5ITVJ?
CTB-1 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHyWJc{UUN3ME2yMlAzOjR4IN88US=> M3XwcnNCVkeHUh?=
MOLT-4 NWnXe2lLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LIUGlEPTB;Mj6zNlg2OyEQvF2= NHLqepdUSU6JRWK=
A101D Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD3TWM2OD1{LkO1NFEh|ryP MUPTRW5ITVJ?
DOHH-2 M4TFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwNEKyO|kh|ryP NHzkSW5USU6JRWK=
ES4 NFq1NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHSz[GJKSzVyPUKuOFMyPTVizszN MXPTRW5ITVJ?
SW780 NXfKcZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjnTWM2OD1{LkWwPFg{KM7:TR?= NF;3NXdUSU6JRWK=
VA-ES-BJ M4HxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjSUmRKSzVyPUKuOVQyOSEQvF2= NWrGW3JnW0GQR1XS
RPMI-8866 MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjGdYh3UUN3ME2yMlU3OjF2IN88US=> MnT1V2FPT0WU
ML-2 NV7YXlZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLvXHZJUUN3ME2yMlU3PTd4IN88US=> NIHYZoFUSU6JRWK=
MSTO-211H MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DRO2lEPTB;Mj61O|Q2OSEQvF2= NUjEe5M4W0GQR1XS
JVM-3 NHHHUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWmxNlQ{UUN3ME2yMlU6OzJ2IN88US=> NF7ZPWtUSU6JRWK=
A3-KAW NUHBNI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv1b2JKSzVyPUKuOlE5OThizszN MoPUV2FPT0WU
DK-MG MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1i2cWlEPTB;Mj62NlQ4OSEQvF2= MlHOV2FPT0WU
LNCaP-Clone-FGC NUH0OlVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[3S5RKSzVyPUKuOlQ{OThizszN MUHTRW5ITVJ?
HT-144 M1Ls[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TqW2lEPTB;Mj62OFU4PyEQvF2= M2XXSHNCVkeHUh?=
NB69 MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXuyV24yUUN3ME2yMlY2OzN2IN88US=> M3yzRnNCVkeHUh?=
A172 M{LaSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwNke1PFgh|ryP NWrnR25yW0GQR1XS
RS4-11 M1y2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PhSmlEPTB;Mj63NlQxPyEQvF2= MmfOV2FPT0WU
DU-4475 NXj4eIZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2eHNKSzVyPUKuO|k2ODJizszN NIHPOmZUSU6JRWK=
SJSA-1 NX3iOlBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1T2lEPTB;Mj64NlU2PiEQvF2= M4\MfnNCVkeHUh?=
BV-173 M3vwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJwOES0N|kh|ryP MVrTRW5ITVJ?
U-2-OS M2H3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nVcGlEPTB;Mj65NVA4KM7:TR?= NH;QVpNUSU6JRWK=
CHP-134 M4j5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PYd2lEPTB;Mj65N|g5OiEQvF2= NWq1N|dGW0GQR1XS
D-502MG NIS0UYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3PVFVKSzVyPUKuPVcyPTRizszN MV7TRW5ITVJ?
KS-1 NHrHenVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwMEG2NlMh|ryP NGfwSYdUSU6JRWK=
A204 M4mzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fwWmlEPTB;Mz6wOVU5QCEQvF2= M1jwRnNCVkeHUh?=
KGN MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLaTWM2OD1|LkC4OFk3KM7:TR?= MYrTRW5ITVJ?
NCI-H292 NWLnWWROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7w[m12UUN3ME2zMlEzODJ6IN88US=> MUDTRW5ITVJ?
CAKI-1 NHTnOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3H5WWlEPTB;Mz6xNlY6PCEQvF2= NHvDbVNUSU6JRWK=
C2BBe1 M1LTb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L6XGlEPTB;Mz6xO|AzPiEQvF2= NGDoTopUSU6JRWK=
NB10 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwMkC5OlYh|ryP MmLtV2FPT0WU
MHH-NB-11 NVvITI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwMk[4Nlch|ryP NIjTN3FUSU6JRWK=
NCI-SNU-1 NEXoZlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ORnloUUN3ME2zMlI4QDR|IN88US=> M3jaRnNCVkeHUh?=
HCT-116 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrCenlIUUN3ME2zMlMxOzN3IN88US=> NXnHSmZwW0GQR1XS
G-401 NICwTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwM{[zNlIh|ryP MmrLV2FPT0WU
MN-60 NHjvNWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmniTWM2OD1|LkS0NFkzKM7:TR?= M13WSnNCVkeHUh?=
SW982 M3jENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonwTWM2OD1|LkWwPFQ5KM7:TR?= MX3TRW5ITVJ?
RKO MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTNwNUO5N|Yh|ryP NWf3fHd[W0GQR1XS
D-283MED NXvMNIVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TEfWlEPTB;Mz61O|k5PiEQvF2= NXftbnBVW0GQR1XS
LB996-RCC MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPVdXJKSzVyPUOuOlI2PThizszN NULab2E3W0GQR1XS
A549 NVrId3J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3T6PGlEPTB;Mz62N|U2OiEQvF2= MoXMV2FPT0WU
LB2241-RCC M37hdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vL[GlEPTB;Mz62OVcxQCEQvF2= MofoV2FPT0WU
SK-HEP-1 NVHoV21JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPDTWM2OD1|Lke0Nlk4KM7:TR?= MoHrV2FPT0WU
G-402 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDjTWM2OD1|LkiwPFMzKM7:TR?= NWnhUmhvW0GQR1XS
GOTO MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nv[GlEPTB;Mz64OFM{OyEQvF2= NI\IbXVUSU6JRWK=
LOXIMVI NIXod3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwOEW2O|Uh|ryP MYDTRW5ITVJ?
NH-12 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTkemlwUUN3ME20MlAyQTV7IN88US=> M2HzVnNCVkeHUh?=
CTV-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUizOZZ6UUN3ME20MlA4QTd|IN88US=> NYjLd5dYW0GQR1XS
CP50-MEL-B M{fGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRwMkSzPVIh|ryP MmfUV2FPT0WU
RH-18 NHLpTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PW[2lEPTB;ND6yO|cxPiEQvF2= M{W5fHNCVkeHUh?=
NB17 NHHPbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;B[XU3UUN3ME20MlMyPzZ6IN88US=> M{jmbXNCVkeHUh?=
A375 NEnU[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRwM{O1NlQh|ryP M37ZPHNCVkeHUh?=
IST-MES1 M2TJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHRTWM2OD12LkSxOFEyKM7:TR?= M3rjXnNCVkeHUh?=
MZ2-MEL NHHrPFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjRZmtoUUN3ME20MlUxOTV3IN88US=> NVHIUZVqW0GQR1XS
CAL-54 M2fZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3IRZFKSzVyPUSuOVMxOTlizszN M3L4VXNCVkeHUh?=
NCI-H28 NX;y[2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRwNkK3NVch|ryP MXjTRW5ITVJ?
D-247MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qyNmlEPTB;ND63OVA4OiEQvF2= M2LTNXNCVkeHUh?=
NCI-H460 M4\qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\kfWlEPTB;ND65NVEzPyEQvF2= M1z5WHNCVkeHUh?=
MCF7 M13Yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HWOmlEPTB;NT60OFI1PCEQvF2= NFSwR|dUSU6JRWK=
697 NHLtN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTVwNES1OUDPxE1? NXXyPJdGW0GQR1XS
ONS-76 M2XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD13LkW3NFA6KM7:TR?= M1\LbHNCVkeHUh?=
C32 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;pWHpKSzVyPUWuOlAxOjlizszN M1zPNHNCVkeHUh?=
OS-RC-2 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7yOpp2UUN3ME21Mlc{QDh5IN88US=> NUS3OpBWW0GQR1XS
MEL-HO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzDNWFMUUN3ME21Mlg2PjZ5IN88US=> M4TaSXNCVkeHUh?=
LoVo M1\wSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\pWmo6UUN3ME22MlAyPjJ2IN88US=> MVvTRW5ITVJ?
AGS M3fueWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTZwMUS4Nlgh|ryP MUfTRW5ITVJ?
GI-ME-N NHfK[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;LN2lEPTB;Nj6yNlQzOSEQvF2= M1npZXNCVkeHUh?=
H-EMC-SS Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLwTWM2OD14LkO4OkDPxE1? MWnTRW5ITVJ?
RVH-421 NGC0VWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXSydodZUUN3ME22MlQzPDJ6IN88US=> MX7TRW5ITVJ?
SW954 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\nZ|RKSzVyPU[uOVU2PzJizszN NH7MbINUSU6JRWK=
NB5 MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjxTphvUUN3ME22MlU3OTh|IN88US=> NFrrTpVUSU6JRWK=
NCI-H2122 M{X5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfCbo9KSzVyPU[uOVg4QTNizszN M{LxcHNCVkeHUh?=
AM-38 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K2PWlEPTB;Nj63OVY{QSEQvF2= MlfvV2FPT0WU
KNS-81-FD NEjVN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfoSXZlUUN3ME22Mlc3PDl2IN88US=> M1nrVnNCVkeHUh?=
LS-513 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTZwN{mwNlYh|ryP MYHTRW5ITVJ?
A427 NIHNemxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnLRVlyUUN3ME22Mlg4QDJ7IN88US=> NIP5V5lUSU6JRWK=
WM-115 NHi5Ro1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZwOUOyN{DPxE1? NV\MZ2NIW0GQR1XS
COLO-829 NHexR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnST2dKSzVyPUeuNlQyQDhizszN MV3TRW5ITVJ?
NCI-H1650 NVzKRWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17sdWlEPTB;Nz6zPVIzQCEQvF2= MXLTRW5ITVJ?
NCI-H358 NEXKRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf0TWM2OD15LkS0PFc6KM7:TR?= NFflUVNUSU6JRWK=
HT-1080 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTdwNEiyOVQh|ryP M4PxU3NCVkeHUh?=
HCC2218 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3rOGNSUUN3ME23MlYzQTdizszN NYGwcYMzW0GQR1XS
NCI-H661 NYrxW49uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLDTWM2OD15Lki3NFY6KM7:TR?= MUPTRW5ITVJ?
KM-H2 M1j2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGzTWM2OD15Lki4Olk1KM7:TR?= M3TubXNCVkeHUh?=
RPMI-2650 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzETWM2OD15Lkm0OFE1KM7:TR?= MnrSV2FPT0WU
NCI-H226 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O4XGlEPTB;OD6yNVEzOiEQvF2= NFnFVWdUSU6JRWK=
MKN45 NWXYdFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rEN2lEPTB;OD6yOlYxOiEQvF2= NUTBV|JCW0GQR1XS
D-392MG NGK1dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DPemlEPTB;OD61NlczOiEQvF2= NYnhUGF7W0GQR1XS
RCC10RGB M{DUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;jbFlTUUN3ME24Mlg3Pjl3IN88US=> NEG0W3RUSU6JRWK=
CAL-51 NHW4[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHpN49KSzVyPUmuNVAzPTFizszN MUPTRW5ITVJ?
COLO-678 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvBTWM2OD17LkOyPFEyKM7:TR?= MYrTRW5ITVJ?
SK-MEL-24 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj4flRDUUN3ME25MlU2QDV4IN88US=> NYrMOmFJW0GQR1XS
SK-MEL-30 NIDBc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0W2lEPTB;OT65OFQ4PiEQvF2= M3rqcnNCVkeHUh?=
MMAC-SF MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjDV3JKSzVyPUGwMlM6PjFizszN NI\2VlNUSU6JRWK=
NTERA-S-cl-D1 M1\o[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjadWZKSzVyPUGwMlY2ODhizszN M3q1VHNCVkeHUh?=
NB12 NETSZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\jU2lEPTB;MUGuOVA{KM7:TR?= MYfTRW5ITVJ?
UACC-257 MljnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFzLki2PVUh|ryP NVjjfFJDW0GQR1XS
LAN-6 M17BdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fNS2lEPTB;MUGuPVkzQCEQvF2= MnvUV2FPT0WU
SW1573 NXrCdGhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF{LkOwPFYh|ryP M4e1PXNCVkeHUh?=
NMC-G1 NITOWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn35TWM2OD1zMj60NVc2KM7:TR?= NFLhOGZUSU6JRWK=
SHP-77 M1PWbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HwNGlEPTB;MUKuOVU4PCEQvF2= NFnNZWpUSU6JRWK=
IGROV-1 NWDTWpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqPFFKSzVyPUGyMlY2PzNizszN M1\SRnNCVkeHUh?=
22RV1 NWTse3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfIW2tKSzVyPUGyMlgxPTlizszN MWrTRW5ITVJ?
SK-MEL-3 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTlTWM2OD1zMz6zPVc{KM7:TR?= NXLKS41KW0GQR1XS
NCI-H1563 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j6d2lEPTB;MUOuOFIxOiEQvF2= Mn:5V2FPT0WU
IGR-1 NVrOXoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPOTWM2OD1zND6wN|Q4KM7:TR?= NV;WeGx2W0GQR1XS
EW-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVL6doZRUUN3ME2xOE4yPjN7IN88US=> NHfoPYtUSU6JRWK=
JEG-3 NVu1OFBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LiSWlEPTB;MUSuOFk2OyEQvF2= MYrTRW5ITVJ?
ES3 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvVTWM2OD1zND62OVYzKM7:TR?= NEDob5lUSU6JRWK=
MDA-MB-175-VII MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HBO2lEPTB;MUSuO|EyOSEQvF2= MoD3V2FPT0WU
P30-OHK NEjWPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTMSlRtUUN3ME2xOU4xPDl4IN88US=> M2jTSnNCVkeHUh?=
GP5d M3HNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7HVGtKSzVyPUG1MlE1PjZizszN MXLTRW5ITVJ?
HMV-II MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF3LkOzN|Mh|ryP NY[3NVQ4W0GQR1XS
COLO-679 M37RZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF3LkWwNUDPxE1? Ml\KV2FPT0WU
JAR NYXxcJByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnVTWM2OD1zNT63NlA2KM7:TR?= Mme4V2FPT0WU
NCI-H1666 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTF3LkmzPVkh|ryP NF3rOllUSU6JRWK=
SW48 NWLjUFVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mme2TWM2OD1zNT65OVE3KM7:TR?= M3HDRnNCVkeHUh?=
NCI-H720 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvnS5dKSzVyPUG1Mlk6QDlizszN MlrHV2FPT0WU
HT-1197 NH2wN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlntTWM2OD1zNj6wN|UzKM7:TR?= NGj2O29USU6JRWK=
HL-60 M4Dxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f5bmlEPTB;MU[uNFM5PCEQvF2= MlHXV2FPT0WU
BEN M1ezdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljkTWM2OD1zNj61OlM5KM7:TR?= MUDTRW5ITVJ?
HAL-01 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1zNj64PVA6KM7:TR?= MYTTRW5ITVJ?
SW900 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDXTWM2OD1zNj65NVMzKM7:TR?= MkTZV2FPT0WU
SBC-1 NHLxS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF5LkW0Nlkh|ryP MYnTRW5ITVJ?
SH-4 NYPB[XJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HOWGlEPTB;MUeuOVg1OSEQvF2= M3Txc3NCVkeHUh?=
UACC-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv6TWM2OD1zNz63OlM4KM7:TR?= M3jGOHNCVkeHUh?=
BHT-101 M2r2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HKbGlEPTB;MUmuPFcxPSEQvF2= M1jiW3NCVkeHUh?=
DB MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTjO3BVUUN3ME2yNU42PjR7IN88US=> Mn7nV2FPT0WU
SK-MEL-1 M4raeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjUNXlmUUN3ME2yNU42QDd{IN88US=> M3e5[XNCVkeHUh?=
NCI-H747 Mlm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK1TWM2OD1{Mj63N|c6KM7:TR?= Mlr1V2FPT0WU
SK-LU-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuTWM2OD1{Mz6zOVI1KM7:TR?= MWXTRW5ITVJ?
KG-1 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHzU2tKSzVyPUKzMlQ6PDZizszN Ml\HV2FPT0WU
LXF-289 M3fETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTJ|LkexOEDPxE1? NV\LRolUW0GQR1XS
HCC1954 NUjvbFl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\xV5NKSzVyPUK0Mlg5PDRizszN NEDDWXVUSU6JRWK=
Ramos-2G6-4C10 NF;acnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33xfmlEPTB;Mk[uOFk5OSEQvF2= NETmSpdUSU6JRWK=
DBTRG-05MG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTOTWM2OD1{Nj62OFg5KM7:TR?= NUXLfo5yW0GQR1XS
NCI-H2052 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTQclBKSzVyPUK3MlU3QDRizszN MXPTRW5ITVJ?
RMG-I M3XiPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX6xdopUUUN3ME2yPU41OTN7IN88US=> MUnTRW5ITVJ?
H9 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j6ZmlEPTB;M{GuN|AxQCEQvF2= NYHFT45nW0GQR1XS
GR-ST M1PEOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN{LkS0OVMh|ryP NHPocINUSU6JRWK=
Mo-T NYfiZ5RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvwTWM2OD1|Mj61NFQ3KM7:TR?= M3naRnNCVkeHUh?=
SW1088 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjzbolKSzVyPUOyMlk5ODFizszN MWrTRW5ITVJ?
LB2518-MEL M1jWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDrTWM2OD1|Mz6wO|k4KM7:TR?= MX3TRW5ITVJ?
NCI-H82 NWW2bHNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHES21XUUN3ME2zN{4yPjZzIN88US=> NIT5TWxUSU6JRWK=
LAMA-84 M{LlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTN2Lk[wO|Mh|ryP MkHYV2FPT0WU
KYSE-450 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\vTWM2OD1|ND62O|c3KM7:TR?= M2nUTnNCVkeHUh?=
LU-99A NVS1S|BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHr3WmxKSzVyPUO1MlAxODdizszN MXnTRW5ITVJ?
BE-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXtSJRKSzVyPUO1MlY2PDVizszN M2\PPXNCVkeHUh?=
GAK NU\sTmNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUexdWxpUUN3ME2zOU43QTVizszN M1X0XnNCVkeHUh?=
NCI-H1573 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjV[o1KSzVyPUO1Mlg5OThizszN NIj0XpFUSU6JRWK=
AsPC-1 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqzTWM2OD1|Nj6xOVI4KM7:TR?= NVTyNZUxW0GQR1XS
HDLM-2 NI[1OmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[4RZVKSzVyPUO2MlMyPiEQvF2= M4HDSnNCVkeHUh?=
NCI-H441 NYHQOmdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTN5LkC2PVEh|ryP NX;MNJVbW0GQR1XS
CAL-27 NXHzdVVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPI[HhxUUN3ME2zO{44OjNzIN88US=> NWnodlM2W0GQR1XS
OVCAR-3 NFK1OlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnqTWM2OD1|OT6zNVgyKM7:TR?= NYDRfmNJW0GQR1XS
RPMI-8226 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN7LkW5PEDPxE1? NXXvcG5XW0GQR1XS
EFO-21 M1jHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M376eWlEPTB;NECuOVgyPCEQvF2= NUX2[HIzW0GQR1XS
SNU-C2B NVnu[mFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ufWlEPTB;NEGuOVA5PCEQvF2= Mlq3V2FPT0WU
VM-CUB-1 M2L0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe1NZRqUUN3ME20N{45ODN5IN88US=> M2D4ZXNCVkeHUh?=
NCI-H2087 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\XdGxJUUN3ME20OU4xOjN|IN88US=> MkfXV2FPT0WU
EW-16 NVfpW2FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIG3d5lKSzVyPUS2MlMyOzdizszN M17jW3NCVkeHUh?=
SK-N-AS NWLCSZNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TrR2lEPTB;NE[uO|E3PyEQvF2= M4\QVXNCVkeHUh?=
COR-L105 M2PIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTR4Lki4OVch|ryP NG\mdI1USU6JRWK=
DEL M{PmfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjlTWM2OD12OD6wOFI6KM7:TR?= MV7TRW5ITVJ?
JVM-2 NVjaO|BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zzdmlEPTB;NEiuNFU2QCEQvF2= MV3TRW5ITVJ?
KARPAS-45 NF22VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1noZmlEPTB;NEmuOFU{QCEQvF2= NIr4[FBUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
体内研究 Nutlin-3α以剂量依赖性方式抑制异种移植物生长,在最高剂量(200毫克/千克)时表现大量的肿瘤收缩。Nutlin-3是p53途径在体内的选择性活化剂,并高度有效地抗SJSA-1骨肉瘤。有野生型p53和MDM2基因扩增的肿瘤对Nutlin-3α治疗应答最好。 [1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
- 合并

Biacore研究:

竞争分析是在Biacore S51进行。甲系列S传感器芯片CM5衍生化用于固定一个PentaHis抗体来捕获His-标记的p53。捕获的水平是〜200响应单位(1单位响应对应于每毫米21 pg的蛋白质)。 MDM2蛋白的浓度被保持恒定在300 nM。将试验化合物溶解于10 mM DMSO中,并进一步稀释使每个MDM2测试样品中的浓度系列抑制剂。该试验是在25¡交流的电泳缓冲液(10 mM HEPES,0.15M的NaCl,2%DMSO)中运行。 MDM2-p53在抑制剂存在下的结合的计算方法是在没有抑制剂的结合的百分比,IC 50是使用微软EXCE计算。
细胞实验:[2]
- 合并
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120小时
  • Method: SRB
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: SJSA-1移植体
  • Dosages: 50, 100, 200 毫克/千克 每天两次
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.97 mM)
Water Insoluble
Ethanol '100 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+55% PEG 300+ddH2O
8mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.49
化学式

C30H30Cl2N4O4

CAS号 675576-98-4
储存条件 粉状
溶于溶剂
别名 (-)-Nutlin-3

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • 回答:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3a | Nutlin-3a供应商 | 采购Nutlin-3a | Nutlin-3a价格 | Nutlin-3a生产 | 订购Nutlin-3a | Nutlin-3a代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID